The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01).
 
Snehal Patel
Employment - Greenwich LifeSciences
Leadership - Greenwich LifeSciences
Stock and Other Ownership Interests - Greenwich LifeSciences
Patents, Royalties, Other Intellectual Property - Greenwich LifeSciences
 
Jaye Thompson
Employment - Greenwich LifeSciences
Leadership - Greenwich LifeSciences
Stock and Other Ownership Interests - Greenwich LifeSciences
Patents, Royalties, Other Intellectual Property - Greenwich LifeSciences
 
F. Daugherty
Leadership - Greenwich LifeSciences
Stock and Other Ownership Interests - Greenwich LifeSciences
Consulting or Advisory Role - Greenwich LifeSciences
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Carrick Pharm; Daiichi-Sankyo; Hengrui Pharmaceutical ; Inatherys; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Relay Tx; Roche; Tempus
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); Roche (Inst); SAGA Dx (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst); Prognosis assessment by a digital pathology assay in early breast cancer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
William Gradishar
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Gilead Sciences; merck; Novartis; Pfizer
 
Miguel Martin
Stock and Other Ownership Interests - AstraZeneca; Pfizer
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - AstraZeneca; Novartis; Roche
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis
 
Hope Rugo
Consulting or Advisory Role - BioNTech; Bristol Meyer; Helsinn Therapeutics; Napo Pharmaceuticals
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Daiichi Sankyo (Inst); F. Hoffman-La Roche/Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Cesar Santa-Maria
Consulting or Advisory Role - Abbvie; Athenex; Bristol-Myers Squibb; Calibr; Calibr; Daiichi Sankyo/Astra Zeneca; Genomic Health; Halozyme; Immunomic Therapeutics; Merck; Natera; Pfizer; Pfizer; Polyphor; Seagen; Zentalis
Research Funding - AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Medimmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - Gilead Sciences; Greenwich LifeSciences
 
Marcus Schmidt
No Relationships to Disclose
 
Laura Spring
Consulting or Advisory Role - AstraZeneca; Daiichi Pharma; Gilead Sciences; Lilly; Novartis; Pfizer; Precede Bio; Seagen
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Lilly (Inst); Merck (Inst)
 
Mothaffar Rimawi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Novartis; Pfizer; Stemline Therapeutics; Tempus
Research Funding - Greenwich LifeSciences (Inst)